In VivoFounded by UK life sciences venture capital firm Medicxi, Centessa Pharmaceuticals is headed up by industry heavyweights. Saurabh Saha, who was formerly Bristol Myers Squibb Company ’s head of R&D
ScripCentessa Pharmaceuticals has launched with a first-of-its-kind model involving the merger of ten biotechs and $250m in series A backing. The new company was created through the merger of ten private
ScripIN VITRO DIAGNOSTICS Adarza Biosystems Inc. Adarza Biosystems Inc. raises $5mm in Series B round Adarza Biosystems Inc. raised $5mm in its Series B financing round led by Cultivation Capital,